Hormone therapyFDA-approvedAdjuvant
Erleada
Generic name: apalutamide
How it works
Blocks androgens from binding to prostate cancer cells, slowing growth.
Cancer types
Prostate Cancer— All patients
Efficacy
Studies show that apalutamide can reduce the risk of cancer recurrence in men with high-risk prostate cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Radiation Therapy with or Without Apalutamide for Recurrent Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Assessing Adherence to Apalutamide in Metastatic Prostate Cancer Patients | Prostate Cancer | preclinical | — | Source → |
| Testing Apalutamide with Hormone Therapy and Radiation for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Evaluating Treatment Intensification for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Skin Moisturization May Help Reduce Apalutamide-Induced Skin Rashes | Prostate Cancer | observational | Grade 3 apalutamide-induced skin rashes occurred in 8.1% of patients in the skin care group and 53.6% of patients in the control group. | Source → |
| Apalutamide and ADT Combination for Prostate Cancer Treatment | Prostate Cancer | phase-3 | — | Source → |
| Testing SX-682 and Apalutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Abiraterone, Apalutamide, and Prednisone in Treating Hormone-Naive Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Docetaxel with Hormonal Therapy and Apalutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Treating Prostate Cancer That Has Recurred After Surgery | Prostate Cancer | phase-3 | — | Source → |
| Study of Prostate Cancer Treatment with Apalutamide or Enzalutamide | Prostate Cancer | phase-3 | — | Source → |
| Testing Apalutamide Alone for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Low Dose Apalutamide for Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Rare Skin Reaction Found in Prostate Cancer Patient Taking Apalutamide | Prostate Cancer | observational | — | Source → |
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | The apalutamide group showed significantly higher CRPC-free probability at 24 months (68.2% vs. 39.8%, p < 0.001) compared to the bicalutamide group. | Source → |
| Prostate Cancer Cells May Resist Apalutamide Treatment | Prostate Cancer | lab-study | — | Source → |
| Apalutamide and PSA Decline in Asian Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Confirmed PSA response rates were higher with apalutamide than placebo: 73.9% versus 33.6% for PSA ≤0.2 ng/mL, 90.1% versus 58.2% for PSA reduction ≥50% [PSA50], and 74.8% versus 25.5% for PSA reduction ≥90% [PSA90]. | Source → |
| Comparing Prostate Cancer Treatments: Abiraterone, Enzalutamide, and Apalutamide | Prostate Cancer | observational | Abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). | Source → |
| Apalutamide Works Better for Some Prostate Cancer Patients | Prostate Cancer | phase-3 | The adjusted hazard ratio for metastasis-free survival was 0.22 (95% CI, 0.17-0.27) for patients with prior local therapy. | Source → |
| Targeting Mitochondria in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| New Guidelines for Using Apalutamide in Prostate Cancer Treatment | Prostate Cancer | review | Increased metastasis-free survival and overall survival following treatment with apalutamide. | Source → |
| Skin Rash Side Effect Found in Chinese Prostate Cancer Patients on Apalutamide | Prostate Cancer | observational | — | Source → |
| Apalutamide therapy linked to longer survival in men with advanced prostate cancer | Prostate Cancer | phase-3 | Apalutamide plus ADT increased the length of time that participants remained alive compared with placebo plus ADT. | Source → |
| Apalutamide Side Effects in Prostate Cancer Patients | Prostate Cancer | review | — | Source → |
| New Study Links Certain Prostate Cancer Drugs to Cardiovascular Risks | Prostate Cancer | observational | — | Source → |
| Apalutamide May Help Prostate Cancer Patients Faster Than Abiraterone | Prostate Cancer | observational | Patients initiated on apalutamide were 53% more likely to achieve PSA90 than those initiated on abiraterone acetate within 6 months. | Source → |
| Apalutamide Improves Survival in Advanced Prostate Cancer | Prostate Cancer | phase-3 | ADT plus apalutamide significantly extends overall survival compared with the standard of care. | Source → |
| Combining Two Treatments Improves Prostate Cancer Outcomes | Prostate Cancer | phase-2 | Patients in the degarelix + apalutamide arm achieved a significantly higher rate of minimal residual disease (MRD) than those in the control arm (38% vs 9.1%). | Source → |
| Combining Apalutamide with Autophagy Inhibitor Reduces Prostate Cancer Tumors | Prostate Cancer | animal-study | Tumor weight was significantly reduced in mice treated with APA + Chl (203.2 ± 5.0) compared to vehicle control (380.4 ± 37.0). | Source → |
| Low Body Weight Linked to Skin Problems in Prostate Cancer Patients on Apalutamide | Prostate Cancer | observational | — | Source → |
| Apalutamide Before Surgery for Prostate Cancer | Prostate Cancer | phase-2 | Median reduction of cancer burden was 41.7%. | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | meta-analysis | Enzalutamide achieved the highest number of life-years (LY, 7.6) and quality-adjusted life-years (QALY, 5.62) compared with apalutamide and ADTs. | Source → |
| Apalutamide Improves Radiotherapy Effectiveness in Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.